BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Niu M, Liu Y, Yi M, Jiao D, Wu K. Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer. Front Immunol 2022;13:827921. [DOI: 10.3389/fimmu.2022.827921] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Li T, Yu J, Hou M, Zha S, Cheng Q, Zheng Q, Li L. Quantitative evaluation of therapy options for relapsed/refractory diffuse large B-cell lymphoma: A model-based meta-analysis. Pharmacol Res 2023;187:106592. [PMID: 36470547 DOI: 10.1016/j.phrs.2022.106592] [Reference Citation Analysis]
2 Yi M, Li T, Niu M, Wu Y, Zhao Z, Wu K. TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy. Front Immunol 2022;13:1061394. [PMID: 36601124 DOI: 10.3389/fimmu.2022.1061394] [Reference Citation Analysis]
3 Gerashchenko GV, Kononenko OA, Bondarenko YM, Stakhovsky EO, Tkachuk ZY, Tukalo MA, Kashuba VI. Expresion paterns of various PDCD1 and PDL1 isoforms in prostate tumors. Biopolym Cell 2022;38:169-185. [DOI: 10.7124/bc.000a7c] [Reference Citation Analysis]
4 Scirocchi F, Strigari L, Di Filippo A, Napoletano C, Pace A, Rahimi H, Botticelli A, Rughetti A, Nuti M, Zizzari IG. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis. Int J Mol Sci 2022;23. [PMID: 36430974 DOI: 10.3390/ijms232214496] [Reference Citation Analysis]
5 Dank M, Mühl D, Herold M, Hornyák L, Szasz AM, Herold Z. Does Elevated Pre-Treatment Plasma PD-L1 Level Indicate an Increased Tumor Burden and Worse Prognosis in Metastatic Colorectal Cancer? JCM 2022;11:4815. [DOI: 10.3390/jcm11164815] [Reference Citation Analysis]
6 Chen Y, He J, Chen R, Wang Z, Dai Z, Liang X, Wu W, Luo P, Zhang J, Peng Y, Zhang N, Liu Z, Zhang L, Zhang H, Cheng Q. Pan-Cancer Analysis of the Immunological Role of PDIA5: A Potential Target for Immunotherapy. Front Immunol 2022;13:881722. [DOI: 10.3389/fimmu.2022.881722] [Reference Citation Analysis]
7 Yang G, Zheng B, Yu Y, Huang J, Zhu H, Deng D, Li J, Liang Z. Electroacupuncture at Zusanli (ST36), Guanyuan (CV4), and Qihai (CV6) Acupoints Regulates Immune Function in Patients with Sepsis via the PD-1 Pathway. BioMed Research International 2022;2022:1-9. [DOI: 10.1155/2022/7037497] [Reference Citation Analysis]
8 Pei L, Zhang Y, Li G, Sun J. Comprehensive Analysis of the Expression and Prognosis for MCM4 in Uterine Corpus Endometrial Carcinoma. Front Genet 2022;13:890591. [DOI: 10.3389/fgene.2022.890591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]